Answers are grounded in this paper and cite their sources.
No standard targeted strategy exists after lorlatinib failure in ALK-rearranged non–small cell lung cancer (NSCLC). We report a 41-year-old man with metastatic ALK-rearranged lung adenocarcinoma who progressed sequentially on alectinib and lorlatinib. Re-biopsy with DNA/RNA next-generation sequencing (NGS) at lorlatinib progression revealed an EML4::ALK fusion with co-occurring ALK I1171N and G1269A mutations at high allele fractions, suggesting a cis configuration. Supported by in vitro data, he received brigatinib plus carboplatin–pemetrexed. After four cycles, the primary tumor regressed markedly, nodal disease showed a complete metabolic response, and intracranial findings remained stable. Grade 2 fatigue was the only adverse event; maintenance pemetrexed plus brigatinib is ongoing. Concurrent chemotherapy and short follow-up preclude attributing the response to brigatinib alone. This case highlights the value of repeat biopsy and NGS after lorlatinib failure and suggests that a brigatinib-containing chemotherapy regimen is feasible in this setting.
No takes yet. Share an insight, caveat, or question.
Akagündüz et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: